Page 22 - GTM-2-1

Global Translational Medicine Mineralocorticoid receptor in CMD

arterial hypertension. Circulation, 131: 2079–2091. to modulate smooth muscle cell function. Endocrinology,
160: 2101–2114.
https://doi.org/10.1161/circulationaha.114.006980
https://doi.org/10.1210/en.2019-00258
79. Omidkhoda N, Vakilian F, Mohammadpour AH, et al., 2020,
Aldosterone and mineralocorticoid receptor antagonists 89. Gueret A, Harouki N, Favre J, et al., 2016, Vascular smooth
on pulmonary hypertension and right ventricular failure: muscle mineralocorticoid receptor contributes to coronary
A review. Curr Pharm Des, 26: 3862–3870. and left ventricular dysfunction after myocardial infarction.
Hypertension, 67: 717–723.
https://doi.org/10.2174/1381612826666200523171137
https://doi.org/10.1161/hypertensionaha.115.06709
80. Maron BA, Opotowsky AR, Landzberg MJ, et al., 2013,
Plasma aldosterone levels are elevated in patients with 90. Kim SK, Biwer LA, Moss ME, et al., 2021, Mineralocorticoid
pulmonary arterial hypertension in the absence of left receptor in smooth muscle contributes to pressure overload-
ventricular heart failure: A pilot study. Eur J Heart Fail, induced heart failure. Circ Heart Fail, 14: e007279.
15: 277–283.
https://doi.org/10.1161/circheartfailure.120.007279
https://doi.org/10.1093/eurjhf/hfs173
91. Gourdie RG, Dimmeler S, Kohl P, 2016, Novel therapeutic
81. Calvier L, Legchenko E, Grimm L, et al., 2016, Galectin-3 strategies targeting fibroblasts and fibrosis in heart disease.
and aldosterone as potential tandem biomarkers in Nat Rev Drug Discov, 15: 620–638.
pulmonary arterial hypertension. Heart, 102: 390–396.
https://doi.org/10.1038/nrd.2016.89
https://doi.org/10.1136/heartjnl-2015-308365
92. Barrera-Chimal J, Girerd S, Jaisser F, 2019, Mineralocorticoid
82. Preston IR, Sagliani KD, Warburton RR, et al., 2013, receptor antagonists and kidney diseases: Pathophysiological
Mineralocorticoid receptor antagonism attenuates basis. Kidney Int, 96: 302–319.
experimental pulmonary hypertension. Am J Physiol Lung https://doi.org/10.1016/j.kint.2019.02.030
Cell Mol Physiol, 304: L678–L688.
93. Stockand JD, Meszaros JG, 2003, Aldosterone stimulates
https://doi.org/10.1152/ajplung.00300.2012
proliferation of cardiac fibroblasts by activating Ki-RasA
83. Boehm M, Arnold N, Braithwaite A, et al., 2018, Eplerenone and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol,
attenuates pathological pulmonary vascular rather than right 284: H176–H184.
ventricular remodeling in pulmonary arterial hypertension.
BMC Pulm Med, 18: 41. https://doi.org/10.1152/ajpheart.00421.2002
94. Wang Q, Cui W, Zhang HL, et al., 2013, Atorvastatin
https://doi.org/10.1186/s12890-018-0604-x
suppresses aldosterone-induced neonatal rat cardiac
84. Kowalski J, Deng L, Suennen C, et al., 2021, Eplerenone fibroblast proliferation by inhibiting ERK1/2 in the genomic
improves pulmonary vascular remodeling and hypertension pathway. J Cardiovasc Pharmacol, 61: 520–527.
by inhibition of the mineralocorticoid receptor in endothelial https://doi.org/10.1097/FJC.0b013e31828c090e
cells. Hypertension, 78: 456–465.
95. Fullerton MJ, Funder JW, 1994, Aldosterone and cardiac
https://doi.org/10.1161/hypertensionaha.120.16196
fibrosis: In vitro studies. Cardiovasc Res, 28: 1863–1867.
85. Lacolley P, Regnault V, Nicoletti A, et al., 2012, The vascular
smooth muscle cell in arterial pathology: A cell that can take https://doi.org/10.1093/cvr/28.12.1863
on multiple roles. Cardiovasc Res, 95: 194–204. 96. Brilla CG, Zhou G, Matsubara L, et al., 1994, Collagen
metabolism in cultured adult rat cardiac fibroblasts:
https://doi.org/10.1093/cvr/cvs135
Response to angiotensin II and aldosterone. J Mol Cell
86. Galmiche G, Pizard A, Gueret A, et al., 2014, Smooth Cardiol, 26: 809–820.
muscle cell mineralocorticoid receptors are mandatory for
aldosterone-salt to induce vascular stiffness. Hypertension, https://doi.org/10.1006/jmcc.1994.1098
63: 520–526. 97. Lother A, Berger S, Gilsbach R, et al., 2011, Ablation of
mineralocorticoid receptors in myocytes but not in fibroblasts
https://doi.org/10.1161/hypertensionaha.113.01967
preserves cardiac function. Hypertension, 57: 746–754.
87. DuPont JJ, McCurley A, Davel AP, et al., 2016, Vascular
mineralocorticoid receptor regulates microRNA-155 to https://doi.org/10.1161/hypertensionaha.110.163287
promote vasoconstriction and rising blood pressure with 98. Fraccarollo D, Bauersachs J, 2011, Cardiomyocyte
aging. JCI Insight, 1: e88942. mineralocorticoid receptor function post myocardial
infarction. Trends Cardiovasc Med, 21: 42–47.
https://doi.org/10.1172/jci.insight.88942
https://doi.org/10.1016/j.tcm.2012.02.003
88. Lu Q, Davel AP, McGraw AP, et al., 2019, PKCδ mediates
mineralocorticoid receptor activation by angiotensin II 99. Fraccarollo D, Berger S, Galuppo P, et al., 2011, Deletion

Volume 2 Issue 1 (2023) 16 https://doi.org/10.36922/gtm.v2i1.229